HSK7653 10 mg Q2W

DRUG2 trials

Sponsors

Sichuan Haisco Pharmaceutical Group Co., Ltd

Conditions

Diabetes Mellitus, Type 2

Phase 3

HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

CompletedNCT04556851

Sichuan Haisco Pharmaceutical Group Co., LtdDiabetes Mellitus, Type 2

Start: 2020-09-29End: 2022-08-08Updated: 2022-12-12

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

CompletedNCT04564872

Sichuan Haisco Pharmaceutical Group Co., LtdDiabetes Mellitus, Type 2

Start: 2020-11-13End: 2022-08-29Updated: 2022-12-12

Related Papers

Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial

Diabetes Obesity and Metabolism2024-10-215 citations

55-OR: HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients With Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

Diabetes2023-06-202 citations